SCHEMBL25572005

SCHEMBL25572005

CC(C)(C)OC(=O)N1CCCC2(CC1)CN(CC1CCNCC1)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
GPR119 Q8TDV5 5/20 0.40
ACACB O00763 1/20 0.37
TPSAB1 Q15661 1/20 0.37
TPSD1 Q9BZJ3 1/20 0.37
TPSG1 Q9NRR2 1/20 0.37
EPHX1 P07099 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
ALDH1A1 P00352 2/20 0.36
CYP2D6 P10635 2/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
USP2 O75604 2/20 0.36
NR1H2 P55055 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25229992 0.95 GPR119 (0.42) HPGDGPR119ACACBDDB1CRBN
SCHEMBL27162617 0.93 CYP2D6 (0.41) HPGDGPR119ACACBTPSAB1TPSD1
SCHEMBL30981206 0.89 ACACB (0.40) GPR119ACACBNR1H2
SCHEMBL26925652 0.87 GPR119 (0.45) HPGDGPR119CYP2D6DDB1CRBN
SCHEMBL27162713 0.86 CYP2D6 (0.38) HPGDGPR119ACACBALDH1A1CYP2D6
SCHEMBL24950413 0.86 ACACB (0.39) HPGDGPR119ACACBDDB1CRBN
SCHEMBL30981400 0.85 CYP11B2 (0.41) GPR119ACACBNR1H2
SCHEMBL23249930 0.85 NR1H2 (0.42) HPGDEPHX1MAPTKDM4ETHRB
SCHEMBL27302369 0.83 GPR119 (0.41) GPR119ACACBUSP2NR1H2
SCHEMBL27142937 0.81 GPR119 (0.49) HPGDGPR119DDB1CRBNUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4186904-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF Ubix Therapeutics, Inc. (KR) 2023-05-31 EP disclosed